Company Profile

Arix Bioscience plc is a United Kingdom-based global venture capital company. The Company is focused on investing in biotechnology companies to deliver superior risk-adjusted returns to shareholders. The Company is engaged in sourcing, financing, and developing healthcare and life science businesses globally. It focuses on late pre-clinical to clinical-stage ventures and covers a diversified range of therapeutic areas. The Company's core portfolio includes Artios Pharma Limited, Aura Biosciences, Inc., Disc Medicine Inc., Ensoma, Harpoon Therapeutics, Inc., Imara, Inc., and Iterum Therapeutics Limited. Its program includes AU-011, ART4215 + talazoparib, Bitopertin, HPN328, HPN217, ART0380, ART4215, and DISC-0974. It has approximately 11 clinical trials and is conducting nine pre-clinical studies. The Company's subsidiaries include Arix Bioscience Holdings Limited, Arix Bioscience, Inc, Arix Capital Management Limited, Arthurian Life Sciences GP Limited, and ALS SPV Limited.

Employees

Sector

Investment Management & Fund Operators

More about the company

11/03/24	Merck Sharp & Dohme LLC completed the acquisition of Harpoon Therapeutics, Inc..	CI
14/02/24	RTW Biotech Opportunities NAV increases 2.5% in January	AN
13/02/24	RTW Biotech Opportunities Completes Arix Bioscience Acquisition	MT
13/02/24	RTW Biotech Opportunities Ltd a fund managed by RTW Investments, LP completed the acquisition of Arix Biosciences Plc's assets from Arix Bioscience plc.	CI
12/02/24	Katoro Gold launches fundraising, eyes board shake-up	AN
12/02/24	Arix Bioscience's Asset Sale to RTW Biotech Takes Effect	MT
12/02/24	Arix Bioscience shares suspended ahead of RTW takeover	AN
12/02/24	Arix Bioscience Shares to be Suspended on London Exchange Amid Acquisition	MT
29/01/24	Arix Bioscience Shareholders Approve Asset Sale to RTW Biotech	MT
23/01/24	Arix Bioscience Gains UK Regulatory Approval for Sale to RTW Biotech	MT
22/01/24	RTW Biotech completes Arix investment in takeover run-up	AN
22/01/24	RTW Biotech Buys Minority Stake in Arix Bioscience to Support Planned Takeover	MT
22/01/24	Arix Bioscience plc Announces Resignation of Directors	CI

25/04/23	Arix Bioscience : Notice of Annual General Meeting 2023	PU
25/04/23	Arix Bioscience : Proxy form for AGM 2023	PU
25/04/23	Arix Bioscience : Annual Report & Accounts to 31 December 2022	PU
13/08/21	Arix Bioscience : Interim Results for the Six Months Ended 30 June 2021	AQ
12/01/21	Arix Bioscience : Artios Pharma Expands US Leadership Team with the Appointment of Abid Ansari as Chief Financial Officer	PU

25/03/21	GenSight Biologics : lance une offre réservée de 25ME
06/11/20	Avis d'analystes du jour : ArcelorMittal, Casino, Crédit Agricole, Getinge, Lanxess, Solutions 30, Thales...
06/11/20	Les marchés s'en fichent, vraiment ?
15/07/20	Avis d'analystes du jour : ArcelorMittal, AXA, BNP Paribas, Clariant, HelloFresh, Moncler, Natixis, Recticel...
15/07/20	Moderna fait son comeback estival

Manager	Title	Age	Since
Tom Davidson DFI	Director of Finance/CFO	-	01/05/2023
Laura Craig IRC	Investor Relations Contact	-	-
Jade Fletcher AUD	Comptroller/Controller/Auditor	-	10/10/2022

Director	Title	Age	Since
Peregrine Moncreiffe CHM	Chairman	75	29/04/2021
Debra Stephanie Barker BRD	Director/Board Member	63	10/08/2022

Arix Bioscience plc Stock

Stocks

ARIX

GB00BD045071

Investment Management & Fund Operators

Latest news : Arix Bioscience plc

Press Releases: Arix Bioscience plc

News in other languages: Arix Bioscience plc

Managers and Directors: Arix Bioscience plc

Latest insider transactions

Venture Capital

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
31/05/23	Robert Lyne	Free	Chief Executive Officer	671,800	0.5200%
04/05/23	Debra Stephanie Barker	Buy	Director	26,000	0.0201%
04/05/23	Robert Lyne	Sell	Chief Executive Officer	22,238	0.0172%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARIX BIOSCIENCE PLC	-.--%	-1.05%	-	-	235M
BB BIOTECH AG	+0.20%	+2.82%	+62.48%	+23.18%	3.35B
HERCULES CAPITAL, INC.	+0.95%	+5.08%	-13.20%	+7.57%	2.94B
HBM HEALTHCARE INVESTMENTS AG	+2.11%	+3.86%	+43.20%	+20.40%	1.94B
MOLTEN VENTURES PLC	-0.76%	+1.15%	+86.83%	+129.11%	1.24B
OCTOPUS APOLLO VCT PLC	0.00%	0.00%	-1.72%	-7.02%	716M
MIRAE ASSET VENTURE INVESTMENT CO., LTD.	+1.39%	-1.85%	+170.33%	+269.23%	674M
OCTOPUS TITAN VCT PLC	0.00%	0.00%	-44.78%	-73.76%	405M
BRITISH SMALLER COMPANIES VCT PLC	0.00%	0.00%	-4.67%	-8.33%	396M
ALBION ENTERPRISE VCT PLC	0.00%	0.00%	-1.83%	-10.79%	372M
Average	+0.39%	+1.32%	+32.96%	+38.84%	1.34B
Weighted average by Cap.	+0.62%	+2.80%	+37.83%	+36.48%